Active, not recruitingPhase 1NCT04451863
Analgesic and Subjective Effects of Terpenes
Studying Primary orthostatic tremor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, Los Angeles
- Principal Investigator
- Ziva Cooper, PhDUniversity of California, Los Angeles
- Intervention
- Low THC(drug)
- Enrollment
- 45 target
- Eligibility
- 21-55 years · All sexes
- Timeline
- 2021 – 2026
Study locations (1)
- University of California, Los Angeles, Los Angeles, California, United States
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04451863 on ClinicalTrials.govOther trials for Primary orthostatic tremor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07340554Neuroimaging of Adolescent Cannabis Use TreatmentIndiana University
- ACTIVE NOT RECRUITINGNCT07582445Perioperative Prospective Follow Up Of Cannabis Consumers and Discrepancy UseHadassah Medical Organization
- RECRUITINGPHASE2NCT07523633Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use DisorderAnders Fink-Jensen, MD, DMSci
- ENROLLING BY INVITATIONNANCT07513337Effects of Cannabis Species Labeling and Marketing on Perceptual, Subjective and Objective Use Outcomes (Aim 2 Study)Johns Hopkins Bloomberg School of Public Health
- RECRUITINGNANCT07056894Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase PsychosisNova Scotia Health Authority
- RECRUITINGNANCT07196462Precision Brain Stimulation to Reduce Cannabis Craving in SchizophreniaVanderbilt University Medical Center
- RECRUITINGPHASE3NCT05052541Safety and Efficacy of Oral Cannabis in Chronic Spine PainUniversity of Colorado, Denver
- RECRUITINGPHASE1NCT07176208Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy AdultsFood and Drug Administration (FDA)